Quality of life of patients with uterine fibroids

封面


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

BACKGROUND: Currently, there is an elevation in the incidence of uterine fibroids in increasingly younger women of reproductive age. Taking into account the current trend of late motherhood, this cohort of patients is interested in using reliable reversible contraception. Combined hormonal contraceptives meet these criteria and are able to neutralize the clinical manifestations of uterine fibroids, thereby improving the quality of life of patients. At the same time, some combined hormonal contraceptives users may experience a decrease in libido and a change in their psycho-emotional state as a manifestation of the side effects of these drugs.

AIM: The aim of this study was to assess the effect of combined hormonal contraceptives on the quality of life in patients with uterine fibroids.

MATERIALS AND METHODS: This study involved 100 patients with uterine fibroids (F3–F6 according to classification of the International Federation of Gynecology and Obstetrics, without indications for surgical treatment) and 30 healthy women aged 18 to 49 years. For contraceptive purposes, 40 participants with uterine fibroids used combined hormonal contraceptives containing ethinyl estradiol (group I) and 60 patients with uterine fibroids did not use any medications (group II). The following validated questionnaires were used for patients with uterine fibroids — at the beginning and after 6 months, and for healthy women in the control group (group III) — once upon entry into the study: Short Form-36, Female Sexual Function Index, and Beck Depression Inventory. A comparative statistical analysis of the studied parameters over time was carried out.

RESULTS: At baseline, a lower quality of life was noted in patients with uterine fibroids compared to the control group (Short Form-36): 94 ± 6 vs 102 ± 11 points, respectively (p < 0.05). After 6 months, patients in group I showed positive dynamics with increasing in the total Short Form-36 from 95 ± 4 to 98 ± 5 points (p < 0.05) compared to patients in group II: 94 ± 6 and 93 ± 5 points (p > 0.05). We revealed no changes in the Female Sexual Function Index in the study groups — at baseline: 24.8 ± 8.9 (group I), 23.9 ± 9.5 (group II), and 27.8 ± 4.7 (group III); and after 6 months: 26.4 ± 9.2 (group I) and 23.9 ± 10.0 (group II) (p > 0.05 for all comparisons). When comparing the results of a questionnaire on the Beck scale, no dynamics were determined in patients with uterine fibroids, including those who used combined hormonal contraceptives.

CONCLUSIONS: The study demonstrated a lower quality of life in patients with uterine fibroids compared to healthy women and an improved quality of life in patients with uterine fibroids using combined hormonal contraceptives. We showed no negative effects of contraceptive drugs on libido and emotional state in women with uterine fibroids who used combined hormonal contraceptives for 6 months.

全文:

受限制的访问

作者简介

Natalia Aganezova

North-Western State Medical University named after I.I. Mechnikov

编辑信件的主要联系方式.
Email: aganezova@mail.ru
ORCID iD: 0000-0002-9676-1570
SPIN 代码: 2961-5377

MD, Dr. Sci. (Med.), Assistant Professor

俄罗斯联邦, 41 Kirochnaya St., Saint Petersburg, 191015

Sergey Aganezov

North-Western State Medical University named after I.I. Mechnikov

Email: aganezov@mail.ru
ORCID iD: 0000-0002-3523-9922
SPIN 代码: 8186-6778

MD, Cand. Sci. (Med.), Assistant Professor

俄罗斯联邦, 41 Kirochnaya St., Saint Petersburg, 191015

Maria Buriak

North-Western State Medical University named after I.I. Mechnikov

Email: mariya.shilo.95@mail.ru
ORCID iD: 0000-0002-7558-8342
SPIN 代码: 8358-5911

MD, postgraduate student

俄罗斯联邦, 41 Kirochnaya St., Saint Petersburg, 191015

参考

  1. Novik AA, Ionova TA. Guidelines for quality of life research in medicine. 2nd ed. YuL Shevchenko editor. Moscow: OLMA Media Group; 2007. (In Russ.) EDN: QLOWXD
  2. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: WHO; 2015 [cited 21.09.2023]. Available from: https://iris.who.int/bitstream/handle/10665/181468/9789241549158_eng.pdf?sequence=9
  3. Federal State Budgetary Institution National Medical Research Center of Obstetrics, Gynecology and Perinatology named after. Academician V.I. Kulakov Ministry of Health of the Russian Federation, Russian Society of Obstetricians and Gynecologists, Russian Society for Contraception. National medical criteria for the acceptability of contraceptive methods. Adapted document “Medical eligibility criteria for the use of WHO contraceptive methods. 5th ed., 2015”. Sukhikh GT, Prilepskaya VN, editors. Moscow; 2023 [cited 21.09.2023]. Available from: https://phlebounion.ru/files/uploads/News/files/2023%20Национальные%20критерии%20приемлемости%20контрацепции%202023.pdf
  4. Burrows LJ, Basha M, Goldstein AT. The effects of hormonal contraceptives on female sexuality: a review. J Sex Med. 2012;9(9):2213–2223. doi: 10.1111/j.1743-6109.2012.02848.x
  5. Lundin C, Danielsson KG, Bixo M, et al. Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle – A double-blind, placebo-controlled randomized trial. Psychoneuroendocrinology. 2017;76:135–143. doi: 10.1016/j.psyneuen.2016.11.033
  6. Lundin C, Wikman A, Lampa E, et al. There is on association between combined oral contraceptives and depression: a Swedish register-based cohort study. BJOG. 2022;129(6):917–925. doi: 10.1111/1471-0528.17028
  7. Munro MG, Critchley HOD, Fraser IS; FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet. 2018;143(3):393–408. doi: 10.1002/ijgo.12666
  8. Instructions for processing data obtained using the SF-36 questionnaire [Internet] [cited 12.01.2024]. Available from: http://therapy.irkutsk.ru/doc/sf36a.pdf (In Russ.)
  9. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(1):191–208. doi: 10.1080/009262300278597
  10. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–571. doi: 10.1001/archpsyc.1961.01710120031004
  11. Ministry of Health of the Russian Federation, LLC “Russian Society of Obstetricians and Gynecologists” (ROAG). Uterine fibroids. Clinical guidelines. Moscow; 2020 [cited 12.01.2024]. Available from: https://minzdravri.ru/wp-content/uploads/2020/12/mioma-matki.pdf (In Russ).
  12. Williams VS, Jones G, Mauskopf J, et al. Uterine fibroids: a review of health-related quality of life assessment. J Womens Health. 2006;15(7):818–829. doi: 10.1089/jwh.2006.15.818
  13. Dilek S, Ertunc D, Tok EC, et al. The effect of myomectomy on health-related quality of life of women with myoma uteri. J Obstet Gynaecol Res. 2010;36(2):364–369. doi: 10.1111/j.1447-0756.2009.01149.x
  14. Davis AR, Castaño PM. Oral contraceptives and libido in women. Annu Rev Sex Res. 2004;15:297–320. doi: 10.1201/b14618-40
  15. Pastor Z, Holla K, Chmel R. The influence of combined oral contraceptives on female sexual desire: a systematic review. Eur J Contracept Reprod Health Care. 2013;18(1):27–43. doi: 10.3109/13625187.2012.728643
  16. Elaut E, Buysse A, De Sutter P, et al. Cycle-related changes in mood, sexual desire, and sexual activity in oral contraception-using and nonhormonal-contraception-using couples. J Sex Res. 2016;53(1):125–136. doi: 10.1080/00224499.2014.976780
  17. Smith NK, Jozkowski KN, Sanders SA. Hormonal contraception and female pain, orgasm and sexual pleasure. J Sex Med. 2014;11(2):462–470. doi: 10.1111/jsm.12409
  18. Lethaby A, Wise MR, Weterings MA, et al. Combined hormonal contraceptives for heavy menstrual bleeding. Cochrane Database Syst Rev. 2019;2(2). doi: 10.1002/14651858.CD000154.pub3
  19. Scheuringer A, Lundin C, Derntl B, et al. Use of an estradiol-based combined oral contraceptives has no influence on attentional bias or depressive symptoms in healthy women. Psychoneuroendocrinology. 2020;113. doi: 10.1016/j.psyneuen.2019.104544
  20. Pagano PH, Zapata BL, Berry-Bibee NE, et al. Safety of hormonal contraception and intrauterine devices among women with depressive and bipolar disorders: a systematic review. Contraception. 2016;94(6):641–649. doi: 10.1016/j.contraception.2016.06.012

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Frequency and severity of depression on the Beck scale at baseline and after 6 months of follow-up of patients with uterine fibroids when using combined hormonal contraceptives

下载 (75KB)
索引源数据
3. Fig. 2. Frequency and severity of depression on the Beck scale at baseline and after 6 months of follow-up of patients with uterine fibroids when using no medications

下载 (72KB)
索引源数据

版权所有 © Eсо-Vector, 2024


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 66759 от 08.08.2016 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия Эл № 77 - 6389 от 15.07.2002 г.


##common.cookie##